Oppenheimer & Co. Inc. acquired a new stake in shares of Rush Street Interactive, Inc. (NYSE:RSI) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,307 shares of the company’s stock, valued at approximately $126,000.
Several other large investors have also recently modified their holdings of the company. JPMorgan Chase & Co. bought a new position in shares of Rush Street Interactive during the fourth quarter valued at about $45,000. Jacobi Capital Management LLC bought a new position in shares of Rush Street Interactive during the first quarter valued at about $49,000. Quantbot Technologies LP bought a new position in shares of Rush Street Interactive during the first quarter valued at about $101,000. Teton Advisors Inc. raised its stake in shares of Rush Street Interactive by 50.0% during the first quarter. Teton Advisors Inc. now owns 22,500 shares of the company’s stock valued at $368,000 after acquiring an additional 7,500 shares during the last quarter. Finally, Alpha Paradigm Partners LLC raised its stake in shares of Rush Street Interactive by 46.4% during the first quarter. Alpha Paradigm Partners LLC now owns 23,772 shares of the company’s stock valued at $388,000 after acquiring an additional 7,539 shares during the last quarter. 15.27% of the stock is owned by hedge funds and other institutional investors.
Top Value Stocks To Own For 2023: Merrimack Pharmaceuticals, Inc.(MACK)
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer primarily in the United States. Its therapeutic oncology candidates in clinical development include MM-398, a nanotherapeutic encapsulation of the chemotherapy drug irinotecan, which is has completed Phase III clinical trials for the treatment of patients with metastatic pancreatic cancer whose cancer had progressed on treatment with the chemotherapy drug gemcitabine; in a Phase I clinical trial as a monotherapy in patients with glioma and in combination with cyclophosphamide in patients with pediatric solid tumors; and in a Phase 1 translational clinical trial designed to identify predictive biomarkers associated with MM-398. The companys therapeutic oncology candidates also include MM-302 that is in Phase II clinical trial for the treatment of patients with ErbB2 (HER2)-positive, locally advanced or metastatic breast cancer; MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer, as well as ovarian, breast, and non-small cell lung cancers; and MM-111 that is in a Phase II clinical trial for the treatment of patients with advanced gastric, esophageal, and gastroesophageal junction cancers. In addition, its therapeutic oncology candidates consist of MM-151 and MM-141, which are in Phase I clinical trials for the treatment of patients with solid tumors. The company has collaboration and license agreements with Baxter International Inc., Baxter Healthcare Corporation, Baxter Healthcare SA, Actavis, Sanofi, PharmaEngine, Inc., Dyax Corp., Adimab LLC, and University of California. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Advisors’ Opinion:
- [By Keith Speights (TMFFishBiz)]
Shares of Tandem Diabetes Care (NASDAQ:TNDM) were jumping 12.9% higher as of 3:51 p.m. EDT on Tuesday. The gain came after S&P Global announced that the stock would be added to the S&P MidCap 400 Index effective Sept. 20.
- [By ]
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has been given an average rating of “Buy” by the ten research firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $127.56.
- [By Beth McKenna]
Shares of Tandem Diabetes Care (NASDAQ:TNDM), the maker of the t:slim X2 insulin pump, rocketed 50.8% higher last month, according to data from S&P Global Market Intelligence. The stock is up a whopping 1,490% over the one-year period through Friday, March 8.
- [By Chris Lange]
When Tandem Diabetes Care Inc. (NASDAQ: TNDM) reported its most recent quarterly results after the markets closed on Tuesday, it said that it had a diluted net loss of $0.02 per share and $76.2 million in revenue. The consensus estimates had called for a net loss of $0.20 per share and $56.34 million in revenue. In the fourth quarter of last year, the medical device firm posted a net loss of $1.23 per share and $40 million in revenue.
Top Value Stocks To Own For 2023: RadiSys Corporation(RSYS)
Radisys Corporation (Radisys), incorporated on March 18, 1987, is a services acceleration company. The Company’s application aware traffic distribution platforms, real-time media processing products and wireless access technologies enable service providers to virtualize and monetize their networks. The Company’s products and services are organized into two segments: Software-Systems, and Embedded Products and Hardware Services.
Software-Systems
The Company’s Software-Systems segment consists of three product families: FlowEngine, MediaEngine and CellEngine. Also included in the Software-Systems segment is its Professional Service organization. FlowEngine focuses on the communication and content provider traffic management market. FlowEngine is a family of products designed to classify and distribute session data flows to network processing resources. FlowEngine products enable communication and content service providers to transition towards network functions virtualization (NFV) architectures by integrating a targeted subset of edge routing, data center switching, and load balancing functionality along with software-defined networking (SDN) control.
The Company’s MediaEngine products are designed into the Internet Protocol (IP) multimedia subsystem (IMS) core of telecom networks and provide the necessary media processing capabilities required for applications, such as audio conferencing, Voice over Long-Term Evolution (VoLTE), Voice over wireless fidelity (Wi-Fi) (VoWifi), Rich Communications Services (RCS) and Web Real-Time Communication (WebRTC). The Company sells a complete high-density system, the MediaEngine MPX-12000, as well as a virtualized software-only virtualized MediaEngine software (vMRF) when its customers choose other lower-density processing platforms. The Company’s MediaEngine provides the media processing capability that enables service providers to deliver audio, video or other multimedia services over their all-IP networks.
The Company’s CellEngine software, which includes its TotalENodeB LTE and Femtotality third-generation (3G) software products, provides the communication linkage between wireless end user devices and mobile core networks through small cell base stations that mobile carriers are deploying to optimize wireless network spectrum utilization and coverage. Its focus is providing software applications, which enable small 3G and LTE operator-controlled, low-power wireless base stations (known as small cells, femtocells, enterprise femtocells and picocells) that enable cellular coverage and provide capacity for homes and enterprises, as well as metropolitan and rural areas.
Embedded Products and Hardware Services
The Company’s Embedded Products and Hardware Services segment provides customers with hardware based products targeted at the communications and healthcare markets. Products within this segment fall under primary categories, including T-Series Advanced Telecommunications Computing Architecture (ATCA) Platforms, Component Object Model (COM) Express and Rackmount Servers, and Other Products. Its segment’s products are predominantly hardware-based products that enable the control and movement of data in both 3G and LTE telecom networks. Its products enable network elements for applications, such as Deep Packet Inspection (DPI), policy management and intelligent gateways (security, femto and LTE gateways).
The Company’s T-Series ATCA product family includes a suite of fully integrated, application ready, software-rich hardware products that are ATCA-based and modular in nature and enable configuration for a range of applications. Based on the standard ATCA form factor, the T-Series ATCA platforms integrate various key products and applications to enable functions within the wireless network core. Its products consist of carrier blades, chassis, disk modules, line cards, and processing and switch modules. The COM Express and Rackmount Servers are targeted primarily at the medical imaging, test and measurement, and aerospace and defense markets. The Company has two primary product families in this category, which include Computer-on-Module Express and Rack Mount Servers. Its Other products comprise of products that are primarily custom built pre-ATCA-based telecommunication products based on earlier technology standards.
The Company competes with Corsa, Noviflow, Dialogic, Dolby, Compunetix, HP, Nokia Solutions and Networks, Aricent Group, NodeH, Artesyn Embedded Technologies, Advantech Co, ADLink Technologies and Kontron AG.
Advisors’ Opinion:
- [By Shane Hupp]
Get a free copy of the Zacks research report on RadiSys (RSYS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Stephan Byrd]
Get a free copy of the Zacks research report on RadiSys (RSYS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Top Value Stocks To Own For 2023: W.R. Grace & Co.(GRA)
W. R. Grace & Co. is engaged in the production and sale of specialty chemicals and specialty materials on a global basis through three operating segments: Grace Catalysts Technologies, which includes catalysts and related products and technologies used in refining, petrochemical and other chemical manufacturing applications; Grace Materials Technologies, which includes packaging technologies and engineered materials used in consumer, industrial, and pharmaceutical applications; and Grace Construction Products, which includes specialty construction chemicals and specialty building materials used in commercial, infrastructure and residential construction. We entered the specialty chemicals industry in 1954, when we acquired both the Dewey and Almy Chemical Company and the Davison Chemical Company. Grace is the successor to a company that began in 1854 and originally became a public company in 1953. Advisors’ Opinion:
- [By Joseph Griffin]
Tyers Asset Management LLC bought a new stake in W. R. Grace & Co (NYSE:GRA) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,464 shares of the specialty chemicals company’s stock, valued at approximately $181,000.
- [By Ethan Ryder]
These are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:
Get W. R. Grace & Co alerts:
W.R. Grace & Co.: Grace Announces Release Date for Second Quarter 2018 Results (twst.com) W. R. Grace & Co (GRA) Expected to Earn Q2 2018 Earnings of $0.90 Per Share (americanbankingnews.com) W. R. Grace & Co (GRA) to Post Q3 2018 Earnings of $0.96 Per Share, Jefferies Financial Group Forecasts (americanbankingnews.com) Venator Materials and Three Additional Specialty Chemicals Stocks on Our Research Desk’s Radar (finance.yahoo.com)
W. R. Grace & Co traded up $0.71, reaching $74.39, on Friday, according to Marketbeat. The stock had a trading volume of 378,610 shares, compared to its average volume of 720,257. W. R. Grace & Co has a fifty-two week low of $58.48 and a fifty-two week high of $77.37. The company has a quick ratio of 1.01, a current ratio of 1.56 and a debt-to-equity ratio of 6.23. The stock has a market cap of $4.96 billion, a PE ratio of 21.88, a PEG ratio of 1.58 and a beta of 1.19.
- [By Max Byerly]
Chemours (NYSE: CC) and W. R. Grace & Co (NYSE:GRA) are both mid-cap basic materials companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.
Top Value Stocks To Own For 2023: Marcus & Millichap, Inc.(MMI)
Marcus & Millichap, Inc., incorporated on June 4, 2013, is a brokerage firm specializing in commercial real estate investment sales, financing, research and advisory services. The Company also offers market research, consulting and advisory services to its clients. It also offers two services to its clients, such as commercial real estate investment brokerage, and financing and ancillary services. It has over 1,600 investment sales and financing professionals in over 80 offices in the United States and Canada that provide investment brokerage and financing services to sellers and buyers of commercial real estate.
The Company divides the commercial real estate market into four segments: Properties with prices approximately $1 million; Private client market, which includes properties priced from $1 million to $10 million; Middle market, which includes properties priced from $10 million to $20 million, and Institutional market, which includes properties priced from $20 million and above. The Company offers different types of properties, such as multifamily, retail, self-storage, hospitality, seniors housing, multifamily tax credit, affordable housing and manufactured housing.
The Company provides its financing services through Marcus & Millichap Capital Corporation (MMCC). MMCC is a broker of debt financing for commercial properties. The Company also provides research, advisory and consulting services to assist clients in forming their investment strategy and making transaction decisions. The Company also provides a range of advisory and consulting services to developers, lenders, owners, real estate investment trusts, high net worth individuals, pension fund advisors and other institutions. The advisory services include opinions of value, operating and financial performance benchmarking analysis, specific asset buy-sell strategies, market and submarket analysis and ranking, portfolio strategies by property type, market strategy, and development and redevelopment feasibility studies.
The Company competes with CBRE Group, Inc., Cushman & Wakefield, Colliers International, HFF, Inc., Jones Lang LaSalle, Walker & Dunlop, Berkadia Commercial Mortgage LLC, Grandbridge Real Estate Capital and NorthMarq Capital, LLC.
Advisors’ Opinion:
- [By Motley Fool Transcribers]
Marcus & Millichap Inc (NYSE:MMI)Q4 2018 Earnings Conference CallFeb. 20, 2019, 5:00 p.m. ET
Contents:
Prepared Remarks Questions and Answers Call Participants
Prepared Remarks:Operator
- [By Shane Hupp]
Marcus & Millichap (NYSE:MMI) was downgraded by analysts at JMP Securities from an “outperform” rating to a “market perform” rating in a report issued on Wednesday, Marketbeat reports.
- [By Logan Wallace]
Marcus & Millichap Inc (NYSE:MMI) major shareholder Phoenix Investments Holdings L sold 3,000 shares of Marcus & Millichap stock in a transaction that occurred on Monday, July 30th. The shares were sold at an average price of $40.27, for a total transaction of $120,810.00. Following the completion of the transaction, the insider now directly owns 16,532,215 shares in the company, valued at approximately $665,752,298.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
